SYNERGISTIC ROLE OF TYPE-I INTERFERONS IN THE INDUCTION OF PROTECTIVE CYTOTOXIC T-LYMPHOCYTES

被引:41
作者
VONHOEGEN, P [1 ]
机构
[1] GERMAN CANC RES CTR,DIV TUMOR IMMUNOL,W-6900 HEIDELBERG,GERMANY
关键词
CYTOLYTIC T LYMPHOCYTE; INTERFERON; ACTIVATION;
D O I
10.1016/0165-2478(95)00065-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Differentiation of cytolytic T cells can be supported by type I and type II interferons (IFN). To characterize the role of type I interferons further we tested the role of recombinant IFN-alpha and IFN-beta on the induction of a weak immune response, against a low immunogenic tumor, which has been shown to be increased by IFN. Both type I interferons IFN-alpha and IFN-beta were able to support the differentiation of cytolytic T lymphocytes (CTL). In case of IFN-alpha no correlation with the antiviral activity could be seen by comparison of IFN-alpha 1 and IFN-alpha 4. The maximal in vitro effects were achieved with very low concentrations in the range of 1-100 IU/ml. IFN-alpha showed the strongest effects, if added in the early phase of the mixed leukocyte culture, whereas IFN-beta was most effective when given at the last day of the culture. In combination, both IFNs gave additional/synergistic effects, whereby addition of IFN-alpha at day 0 and IFN-beta at day 4 led to maximal specific CTL responses. In vivo augmentation of the anti-tumor immune response by both types of IFNs supported the in vitro findings and also the synergistic effect of both types of IFNs could be demonstrated. Therefore we propose that IFN-alpha is relevant in the induction of CTL responses, i.e., the conversion of precursor T cells into mature cells and growth promotion whereby IFN-beta might trigger the lytic machinery of the cells and promote differentiation. This synergistic efficacy is also operative in tumor rejection.
引用
收藏
页码:157 / 162
页数:6
相关论文
共 19 条
[1]   INTERFERONS IN THE THERAPY OF SOLID TUMORS [J].
AGARWALA, SS ;
KIRKWOOD, JM .
ONCOLOGY, 1994, 51 (02) :129-136
[2]   ANTI-TUMOR EFFECTS OF INTERFERON IN MICE INJECTED WITH INTERFERON-SENSITIVE AND INTERFERON-RESISTANT FRIEND-LEUKEMIA CELLS .1. [J].
BELARDELLI, F ;
GRESSER, I ;
MAURY, C ;
MAUNOURY, MT .
INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (06) :813-820
[3]   INTERFERON - A CYTOTOXIC LYMPHOCYTE-T DIFFERENTIATION SIGNAL [J].
CHEN, LK ;
TOURVIEILLE, B ;
BURNS, GF ;
BACH, FH ;
MATHIEUMAHUL, D ;
SASPORTES, M ;
BENSUSSAN, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1986, 16 (07) :767-770
[4]  
COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598
[5]   VIRAL HEMAGGLUTININ AUGMENTS PEPTIDE-SPECIFIC CYTOTOXIC T-CELL RESPONSES [J].
ERTEL, C ;
MILLAR, NS ;
EMMERSON, PT ;
SCHIRRMACHER, V ;
VONHOEGEN, P .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (10) :2592-2596
[6]   SIGNIFICANT DIFFERENCES IN THERAPEUTIC RESPONSES TO A HUMAN INTERFERON-ALPHA-B/D HYBRID IN RAUSCHER OR FRIEND MURINE LEUKEMIA-VIRUS INFECTIONS [J].
GANGEMI, JD ;
MATTER, A ;
PONCIONI, B ;
HOCHKEPPEL, HK .
JOURNAL OF INTERFERON RESEARCH, 1989, 9 (03) :275-283
[7]   HOST HUMORAL AND CELLULAR IMMUNE-MECHANISMS IN THE CONTINUED SUPPRESSION OF FRIEND-ERYTHROLEUKEMIA METASTASES AFTER INTERFERON -ALPHA/BETA TREATMENT IN MICE [J].
GRESSER, I ;
CARNAUD, C ;
MAURY, C ;
SALA, A ;
EID, P ;
WOODROW, D ;
MAUNOURY, MT ;
BELARDELLI, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (05) :1193-1203
[8]   LYMPHOCYTE-MEDIATED CYTOTOXICITY - 2 PATHWAYS AND MULTIPLE EFFECTOR MOLECULES [J].
HENKART, PA .
IMMUNITY, 1994, 1 (05) :343-346
[9]   CELL TYPE SPECIFIC EXPRESSION AND REGULATION OF MURINE INTERFERON-ALPHA AND INTERFERON-BETA GENES [J].
HOSSHOMFELD, A ;
ZWARTHOFF, EC ;
ZAWATZKY, R .
VIROLOGY, 1989, 173 (02) :539-550
[10]   SUCCESSFUL IMMUNOTHERAPY OF THE HIGHLY METASTATIC MURINE ESB LYMPHOMA WITH SENSITIZED CD8+ T-CELLS AND IFN-ALPHA/BETA [J].
KAIDO, T ;
MAURY, C ;
SCHIRRMACHER, V ;
GRESSER, I .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (04) :538-543